Premium
Apolipoprotein B and apolipoprotein A‐I: risk indicators of coronary heart disease and targets for lipid‐modifying therapy
Author(s) -
Walldius G.,
Jungner I.
Publication year - 2004
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1046/j.1365-2796.2003.01276.x
Subject(s) - apolipoprotein b , medicine , coronary heart disease , cholesterol , risk factor , endocrinology , disease , cardiology , ldl cholesterol , lipoprotein
. Although LDL cholesterol (LDL‐C) is associated with an increased risk of coronary heart disease, other lipoproteins and their constituents, apolipoproteins, may play an important role in atherosclerosis. Elevated levels of apolipoprotein (apo) B, a constituent of atherogenic lipoproteins, and reduced levels of apo A‐I, a component of anti‐atherogenic HDL, are associated with increased cardiac events. Apo B, apo A‐I and the apo B/apo A‐I ratio have been reported as better predictors of cardiovascular events than LDL‐C and they even retain their predictive power in patients receiving lipid‐modifying therapy. Measurement of these apolipoproteins could improve cardiovascular risk prediction.